Novel TNF antagonists for the treatment of rheumatoid arthritis (Q37650386)

21 August 2017

1 reference

title

Novel TNF antagonists for the treatment of rheumatoid arthritis (English)

1 reference

21 August 2017

0 references

1 reference

Eric M Ruderman

2

0 references

author name string

Laisvyde Statkute

series ordinal

1

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 January 2010

1 reference

Expert Opinion on Investigational Drugs

21 August 2017

published in

1 reference

21 August 2017

volume

19

1 reference

21 August 2017

issue

1

1 reference

21 August 2017

page(s)

105-115

1 reference

Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517/13543780903438559

Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903438559

Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903438559

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903438559

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903438559

A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903438559

The impact of PEGylation on biological therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903438559

Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903438559

Certolizumab use in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903438559

Certolizumab pegol for the treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903438559

Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903438559

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903438559

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903438559

Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903438559

Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903438559

Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903438559

Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903438559

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903438559

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903438559

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903438559

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903438559

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903438559

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903438559

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903438559

Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903438559

Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903438559

10.1517/13543780903438559

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference